Peptide-based modulators of HMGB1 activity protect against cell damage and inflammation
The proposed technology assists with the inhibition of the HMGB1, therefore, decreasing the body’s inflammatory response which occurs when the HMGB1 protein binds to DNA and TLR4. By decreasing HMGB1 binding to DNA, cell inflammation can be significantly reduced and therefore preventing further cell damage. This technology can be used in a large spectrum of diseases, such as diabetic complications, hypertension, systemic inflammation, acute chronic heart, kidney, and liver diseases.
Chronic cell inflammation plays a pivotal role in cell damage and inflammation of the body’s cells is a major side effect of many different diseases. Current technologies that aim at trying to reduce cell inflammation are supplementing the body with foods that have anti-inflammatory properties, as well as the use of infrared led exposure. However, oftentimes eating these certain foods may not be sufficient enough to repair excessive inflammation. Infrared light exposure can cause numerous side effects, such as irritability and insomnia. By inhibiting HMGB1 using peptide-based modulators, the body’s natural response to trigger inflammation can be decreased. This new technology prohibits the release of pro-apoptotic and pro-inflammatory proteins, which typically occur when HMGB1 binds to DNA and TLR4.
- Treatment of pulmonary arterial hypertension (PAH) in heart disease
- Used to treat cell inflammation and damage in diseases including but not limited to:
- Diabetic complications
- Systemic inflammation
- Acute and chronic heart disease
- Kidney and liver diseases
- Wide variety of uses
- Significantly fewer side effects than other technologies in the field
- Significant decrease in further cell damage
- Is a proactive approach, as opposed to reactive
TTO Home Page: https://arizona.technologypublisher.com
Name: Mitch Graffeo
Title: Sr. Licensing Manager - COM-T